Is Zykadia a chemotherapy drug and how does it work?
Zykadia (ceritinib) is a chemotherapy drug used to treat a certain type of lung cancer called ALK (anaplastic lymphoma kinase)-positive non-small cell lung cancer (NSCLC).
Zykadia is a small molecule drug and a type of targeted therapy. Unlike traditional chemotherapy drugs that attack all dividing cells, damaging healthy cells as well as cancerous ones, Zykadia is a targeted chemotherapy drug that targets ALK.
Mutations in the ALK gene, which provides the instructions for making a protein called ALK receptor tyrosine kinase, are found in about five percent of people with lung cancer.
How does Zykadia work in patients with non-small cell lung cancer?
Zykadia works by blocking certain receptors on cancer cells, which prevents them from growing. Zykadia is a kinase inhibitor that works primarily by blocking the ALK receptor tyrosine kinase, which is why it is used to treat ALK-positive NSCLC.
In some people who develop NSCLC, the ALK gene is turned on and fuses or joins with other genes to form an ALK rearrangement or fusion, which causes them to develop cancer.
Receptor tyrosine kinases are proteins that play a variety of key roles involved in the growth, motility, differentiation and metabolism of cells. Mutations or other problems with these tyrosine kinases can lead to the development of different types of cancer.
References
- Food and Drug Administration (FDA). Zykadia. [Accessed October 4, 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s003lbl.pdf.
- American Cancer Society. How Targeted Therapies Are Used to Treat Cancer. January 29, 2021. [Accessed October 4, 2021]. Available from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/what-is.html.
- ALK Positive. What is ALK-Positive Lung Cancer? [Accessed October 4, 2021]. Available from: https://www.alkpositive.org/what-is-alk.
- Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. Published 2018 Feb 19. doi:10.1186/s12943-018-0782-4.
- Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;9:188. Published 2010 Jul 13. doi:10.1186/1476-4598-9-188.
Read next
Related medical questions
- How aggressive is non-small cell lung cancer?
- Does smoking cause non-small cell lung cancer?
- What type of lung cancer is Vizimpro used to treat?
- What type of cancer is Tecentriq used to treat?
- How long does it take for Keytruda to work?
- Why give Taxol (Paxel) before carboplatin?
- What is the difference between Opdivo and Keytruda?
- Pembrolizumab vs. nivolumab: How do they compare?
- What is Paxel called in the USA?
- How effective is Lumakras, what's the survival rate?
- How effective is Tabrecta?
- How does erlotinib work (mechanism of action)?
- How long can I take Gilotrif (afatinib) for?
- What is the difference between Mvasi and Avastin?
- How does Retevmo work?
- Will Tabrecta cure lung cancer?
- Are there cost-saving programs for Tecentriq?
- Is Tabrecta a chemotherapy drug?
- What is the mechanism of action for Alecensa (alectinib)?
- Is Gilotrif (afatinib) a chemotherapy drug?
- Can Tarceva (erlotinib) cure lung cancer?
- Is atezolizumab (Tecentriq) a chemotherapy or immunotherapy drug?
- How effective is atezolizumab (Tecentriq)?
- How long do you take Alecensa for?
- How effective is Alecensa for ALK-positive NSCLC?
- How do Exkivity and Rybrevant compare for NSCLC?
- How does Gilotrif (afatinib) work?
- How does pemetrexed work?
- How does Rybrevant work?
- How effective is Exkivity (mobocertinib) for NSCLC?
Drug information
- Zykadia Information for Consumers
- Zykadia prescribing info & package insert (for Health Professionals)
- Side Effects of Zykadia (detailed)
Related support groups
- Zykadia (2 questions, 3 members)
- Non-Small Cell Lung Cancer (52 questions, 70 members)